RxDoctor Payments Data

Regan Douty, DO

Internal Medicine · Redlands, CANPI 1295766442

Payments from drug & device makers

$1,274in general payments, 2019–2025

Across 80 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$226
  • Boehringer Ingelheim$142
  • Lilly USA, LLC$124
  • AstraZeneca$107
  • Pfizer$90
  • Bayer$86
  • plus $499 from 12 others

What the payments were for

  • Food & beverage$1,25599%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,274 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$68,253
Medicare patients
206
Services billed
1,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban249$260,289
JardianceEmpagliflozin59$69,829
XareltoRivaroxaban80$64,572
JanuviaSitagliptin Phosphate50$59,696
OzempicSemaglutide64$59,504
FarxigaDapagliflozin Propanediol20$24,725
TrulicityDulaglutide21$24,718
Humulin R U-500 KwikpenInsulin Regular, Human12$23,164
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog40$22,863
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,217
Atorvastatin Calcium1,296$14,458
DuleraMometasone/Formoterol25$12,778
PremarinEstrogens, Conjugated16$11,039
SymbicortBudesonide/Formoterol Fumarate34$9,690
Repatha SyringeEvolocumab15$9,263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$90$271,328265 claims
Boehringer IngelheimJardiance, Combivent Respimat$142$75,29770 claims
MerckJanuvia, Dulera$85$72,47475 claims
Johnson & JohnsonXarelto$58$64,57280 claims
Novo NordiskOzempic$226$59,50464 claims
AstraZenecaFarxiga, Symbicort$107$34,41554 claims
Lilly USA, LLCTrulicity$124$24,71821 claims
GSKTrelegy Ellipta, Breo Ellipta$43$23,81632 claims
NovartisEntresto$41$9,11014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →